the present invention relates to cinacalcet for use in the treatment of ganglioneuroblastomas and in another particular embodiment the present invention relates to cinacalcet for use in the treatment of ganglioneuromas as mentioned in the background section u s pat no 5 688 938 describes nps r 568 as the most active casr agonist compound in that regard comparative assays have been carried out in the present invention to compare the effects of using cinacalcet and r 568 in the treatment of neuroblastic tumors surprisingly cinacalcet has a series of advantages with respect to nps r 568 from the pharmacological and pharmacodynamic viewpoint one of the most significant and surprising effects of cinacalcet is apoptosis induction at concentrations that are significantly lower than nps r 568 fig2 table 1 this entails significant advantages of cinacalcet with respect to other casr agonists since it allows effective treatment with the administration of a lower dose of pharmaceutical product which generally involves greater treatment tolerance and less risk of occurrence of side effects or toxicity in addition to facilitating administration and administration regimen these advantages are particularly relevant when a drug must be administered in a prolonged manner over time as is the case of cinacalcet administered for the treatment of neuroblastic tumors relapses of these tumors occur.